Related coverage linked through entity extraction aliases.
Aug 24, 2026
A study in Diabetologia shows type 2 diabetes in lean Africans is driven by insulin shortage, not insulin resistance, and may require different treatment than standard guidelines. The study analyzed data from over 3,300 African adults and found distinct complication patterns between lean and overweight patients.
Aug 19, 2026
New research shows GLP-1 receptor agonists are associated with reduced asthma exacerbation risk in overweight, obese, and morbidly obese patients without diabetes, with risk reductions of 14.6%, 12.2%, and 13.3% respectively. The findings were presented at the 2026 AAAAI Annual Meeting.
Aug 18, 2026
Michelle, a mental health therapist, was diagnosed with stage 4 lung cancer and given 24 months to live. Through yoga and meditation, she shifted her mindset and is now thriving six years after diagnosis, with tumors continuing to shrink.
Aug 18, 2026
The White House reports a 3.1% drop in prescription drug prices over the past year, the steepest decline since 1963, attributing it to President Trump's Most Favored Nation policies and TrumpRx discounts. Drugmakers like Pfizer have agreed to significant price cuts on several medications.
Aug 08, 2026
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Jul 23, 2026
Bristol Myers Squibb, Sanofi, and Pfizer have filed new patent infringement suits over drugs including Camzyos, Lantus, and abrocitinib, while the Federal Circuit denied Sarepta's rehearing bid in a Regenxbio DNA patent case.
Jul 04, 2026
Removing olfactory groove meningioma may improve blood sugar control in diabetes patients, a JAMA Network Open study finds. Both intermittent and continuous calorie restriction also improve metabolic health in type 2 diabetes.
Jul 28, 2026
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
Aug 01, 2026
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
May 15, 2026
New AI tools predict diabetic kidney disease from retinal images, flag hemodialysis patients at hospitalization risk, and advance lupus nephritis care. Findings were presented at ARVO 2026 and published in NEJM Catalyst, The Lancet, and the International Journal of Molecular Sciences.
Aug 04, 2026
New research: any cardiometabolic risk factor justifies MASLD screening in overweight adults, and MASLD independently worsens sepsis, bleeding, and other outcomes in hospitalized Crohn's disease patients.
Apr 29, 2026
Global biologics market projected to grow to USD 1.28 trillion by 2035; Japan cell and gene therapy market to reach USD 2.15 billion by 2034; Japan biologic drug lifecycle management market to hit USD 9.69 billion by 2033.
Aug 04, 2026
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
Jul 07, 2026
Novo Nordisk partners with OpenAI to speed drug discovery, with pilots by 2026. AI is moving beyond hype into pharma R&D, reflected in major collaborations and new FDA guidance.
Aug 01, 2026
A study of over 85,000 women found that insurance coverage and healthcare access significantly affect folic acid use, increasing preventable birth defect risks. The findings support fortification efforts, while a University of Houston initiative aims to address pharmacy access barriers.
Apr 30, 2026
Japan's Intellectual Property High Court upheld three Boehringer Ingelheim patents for linagliptin, rejecting challenges by Nipro. It also upheld the revocation of a separate dosage patent, calling the regimen a routine refinement within known ranges.
Jul 10, 2026
Australian and US regulators have warned about sexual enhancement and honey products containing undeclared prescription medicines, prompting recalls and safety alerts. UK regulators also caution about underreported drug-herb interactions and herb-induced liver injury.
Aug 08, 2026
Lupin reported record Q3 FY2026 revenue of INR 7,168 crores and a 31.1% EBITDA margin, while preparing to launch a generic semaglutide and shifting focus to innovation. The company also secured US FDA approval for Pegfilgrastim and EU approval for ranibizumab biosimilar.
Jul 21, 2026
The FDA moved to exclude semaglutide, tirzepatide and liraglutide from its 503B compounding list. Eli Lilly won U.S. approval for its oral pill Foundayo, and Novo Nordisk sued Lilly over allegedly misleading weight-loss ads.
Aug 08, 2026
Recent studies on metformin and age-related macular degeneration report conflicting findings: a JAMA Ophthalmology cohort found no association, while studies in Ophthalmology Retina and BMJ Open Ophthalmology found reduced odds of neovascular and intermediate AMD, respectively. All were observational.
